“The reality of the matter is business develops medication — it’s important to work with business. The difficulty is disclosure in publication,” stated Ellen V. Sigal, the founder and chairwoman of the nonprofit Mates of Most cancers Analysis, which accepts business funding. “Rob has finished many, many scientific trials with business, however he has not been a pawn of business. He’s fully dedicated to transparency, integrity and science.”
Dr. Aaron S. Kesselheim, who served on the F.D.A. advisory panel that thought of the Alzheimer’s drug and resigned from the committee after it was permitted, stated Dr. Califf’s background working scientific trials could be beneficial for main the company.
“I don’t suppose it’s essentially disqualifying,” stated Dr. Kesselheim, a professor of drugs at Harvard Medical College and Brigham and Ladies’s Hospital. “I feel the truth that he labored for such a very long time in scientific trials demonstrates that he has experience in understanding what goes into a great scientific trial. Hopefully, he can carry that into his position as an F.D.A. commissioner.”
However Dr. Kesselheim objected to Dr. Califf’s efforts, when he was the commissioner, to permit drug firms to promote off-label makes use of for his or her merchandise, noting that sufferers will be endangered by medication which are prescribed for makes use of that the F.D.A. has not permitted. “That to me is a pink flag,” Dr. Kesselheim stated. “Hopefully, he’s moved previous that as an thought, as a result of it will be a horrible thought.”
Throughout his first tenure on the company, Dr. Califf centered on modernizing the gathering and use of digital well being information to reply questions on medication and medical units that would not be gleaned from scientific trials.
He additionally sought to extend the usage of “real-world proof” — case research and particular person affected person experiences — to tell regulatory selections. Some public well being specialists worry that counting on information outdoors of randomized scientific trials endangers sufferers; Dr. Califf believes there’s room for each approaches.
His willingness to think about such information brought about controversy in 2016, when the Meals and Drug Administration overruled its specialists to approve a brand new drug for therapy of a uncommon, deadly muscle illness, regardless of lack of proof that it labored.